NEW YORK (Reuters Health) – Very small breast tumors that generate extensive lymph node involvement may be more biologically aggressive than larger tumors with the same degree of…
NEW YORK (Reuters Health) – Results of a meta-analysis confirm that the oral tyrosine kinase inhibitor gefitinib is effective as first-line therapy in patients with advanced non-small-cell lung…
Teresa L. Knight, MD, FACOG, Chief Medical Officer of the Women’s Health Specialists of Saint Louis, discusses HPV and cervical cancer. To learn more about the Women’s Health…
NEW YORK (Reuters Health) – In patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC), high doses of ursodeoxycholic acid (UDCA) are associated with an increased risk…
NEW YORK (Reuters Health) – Even when small, nonfunctioning pancreatic endocrine tumors are likely to be aggressive, and should be removed when they are discovered incidentally, according to…
NEW YORK (Reuters Health) – Use of the radioprotective agent amifostine to reduce xerostomia and other side effects in cancer patients undergoing radiation therapy does not decrease survival,…
NEW YORK (Reuters health) – Among premenopausal women treated for hormone-responsive breast cancer with adjuvant anastrozole, body mass index (BMI) has a significant impact on outcomes, an Austrian…
NEW YORK (Reuters Health) – Roughly one-third of venous thromboembolism (VTE) events that occur in patients who’ve had surgery for cancer happen after they leave the hospital, with…
NEW YORK (Reuters Health) – For children and adolescents with conditions that require frequent placement of intravenous lines, administration of 50% nitrous oxide makes the process of IV…
NEW YORK (Reuters Health) – Ovarian suppression, using a luteinizing hormone-releasing hormone agonist, during neoadjuvant chemotherapy for breast cancer in premenopausal women does not help preserve subsequent ovarian…